Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Neoplasms 27Colorectal Neoplasms 20Breast Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 13Neoplasm Metastasis 12Lung Neoplasms 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Melanoma 9Lymphoma, Non-Hodgkin 8Small Cell Lung Carcinoma 6Recurrence 6Liver Neoplasms 6Leukemia 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Prostatic Neoplasms 5Glioblastoma 5Cholangiocarcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Gastrointestinal Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

pembrolizumab 3napabucasin 3Bevacizumab 3entinostat 2Paclitaxel 2Ocoxin 2Leucovorin 2Irinotecan 2Immunotherapy 2Gemcitabine 2Fluorouracil 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vorasidenib 1sipuleucel-T 1pralsetinib 1palbociclib 1luprolide acetate gel depot 1linifanib 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1durvalumab 1catumaxomab 1Vaccines 1VB6-845 fusion protein 1Taxes 1Sorafenib 1Pemetrexed 1Papillomavirus Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Glandular and Epithelial × Drug Therapy × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡